Literature DB >> 31314588

Downregulated Long Noncoding RNA GAS5 Fails to Function as Decoy of CEBPB, Resulting in Increased GDF15 Expression and Rapid Ovarian Cancer Cell Proliferation.

Lin-Lin Guo1, Shan-Feng Wang1.   

Abstract

Introduction: Growth differentiation factor 15 (GDF15), a newly identified member of transforming growth factor (GDF) superfamily, is upregulated in ovarian (OV) cancer. Upregulated GDF15 positively correlates with poor prognosis of OV cancer. Thus, elucidation of the mechanism underlying GDF15 overexpression is important. Method and
Results: PROMO and JASPAR prediction software were used to find transcription factors for GDF15 expression. Data from TCGA database were analyzed to find long noncoding RNAs (lncRNAs) that were also abnormally expressed in OV cancer and had associations with GDF15 expression. Transcription factor CEBPB was predicted as an important regulator of GDF15, confirmed by luciferase reporter assay. However, CEBPB expression was not significantly changed in OV cancer. Data from TCGA database showed that lncRNA GAS5 is downregulated in OV cancer and its expression is negatively correlated with GDF15 expression. RPISeq showed high affinity of GAS5 to CEBPB and this was confirmed by RNA-binding protein immunoprecipitation assay. GAS5 overexpression increased its binding to CEBPB and consequently downregulated GDF15. GAS5 overexpression and GDF15 knockdown decreased viability and increased apoptosis of OV cancer cells, but CEBPB overexpression had opposite effects. However, simultaneous GAS5 and CEBPB overexpression or CEBPB overexpression together with GDF15 knockdown had no effect on cell viability and apoptosis.
Conclusion: GAS5 functions as decoy of CEBPB, blocking transcription-promoting effect of CEBPB on GDF15.

Entities:  

Keywords:  CEBPB; GDF15; lncRNA GAS5; ovarian cancer cells

Mesh:

Substances:

Year:  2019        PMID: 31314588     DOI: 10.1089/cbr.2019.2889

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  7 in total

Review 1.  Macrophage inhibitory cytokine-1 in cancer: Beyond the cellular phenotype.

Authors:  Sakthivel Muniyan; Ramesh Pothuraju; Parthasarathy Seshacharyulu; Surinder K Batra
Journal:  Cancer Lett       Date:  2022-03-26       Impact factor: 9.756

Review 2.  The Challenges and Opportunities of LncRNAs in Ovarian Cancer Research and Clinical Use.

Authors:  Martín Salamini-Montemurri; Mónica Lamas-Maceiras; Aida Barreiro-Alonso; Ángel Vizoso-Vázquez; Esther Rodríguez-Belmonte; María Quindós-Varela; María Esperanza Cerdán
Journal:  Cancers (Basel)       Date:  2020-04-21       Impact factor: 6.639

Review 3.  The Non-Coding RNA GAS5 and Its Role in Tumor Therapy-Induced Resistance.

Authors:  George I Lambrou; Kyriaki Hatziagapiou; Apostolos Zaravinos
Journal:  Int J Mol Sci       Date:  2020-10-15       Impact factor: 5.923

4.  Long Noncoding RNA GAS5 Accelerates Cholangiocarcinoma Progression by Regulating hsa-miR-1297.

Authors:  Qian Li; Lei Fu; Lili Han; Shuai Li; Yanling Zhang; Jufeng Wang
Journal:  Cancer Manag Res       Date:  2021-03-23       Impact factor: 3.989

Review 5.  LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms.

Authors:  Eleonora A Braga; Marina V Fridman; Alexey A Moscovtsev; Elena A Filippova; Alexey A Dmitriev; Nikolay E Kushlinskii
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

6.  Identification of a Novel Immune-Related lncRNA CTD-2288O8.1 Regulating Cisplatin Resistance in Ovarian Cancer Based on Integrated Analysis.

Authors:  Tingwei Liu; Jiacheng Shen; Qizhi He; Shaohua Xu
Journal:  Front Genet       Date:  2022-02-14       Impact factor: 4.599

7.  Genetic variations in UCA1, a lncRNA functioning as a miRNA sponge, determine endometriosis development and the potential associated infertility via regulating lipogenesis.

Authors:  Cherry Yin-Yi Chang; Li Yang; Joe Tse; Lun-Chien Lo; Chung-Chen Tseng; Li Sun; Ming-Tsung Lai; Ping-Ho Chen; Tritium Hwang; Chih-Mei Chen; Fuu-Jen Tsai; Jim Jinn-Chyuan Sheu
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.